FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378232840> ?p ?o ?g. }

• W4378232840 abstract "Background Anti-GAD65 autoantibodies (GAD65-Abs) may occur in patients with epilepsy and other neurological disorders, but the clinical significance is not clear-cut. Whereas high levels of GAD65-Abs are considered pathogenic in neuropsychiatric disorders, low or moderate levels are only considered as mere bystanders in, e.g., diabetes mellitus type 1 (DM1). The value of cell-based assays (CBA) and immunohistochemistry (IHC) for GAD65-Abs detection has not been clearly evaluated in this context. Objective To re-evaluate the assumption that high levels of GAD65-Abs are related to neuropsychiatric disorders and lower levels only to DM1 and to compare ELISA results with CBA and IHC to determine the additional value of these tests. Methods 111 sera previously assessed for GAD65-Abs by ELISA in routine clinical practice were studied. Clinical indications for testing were, e.g., suspected autoimmune encephalitis or epilepsy (neuropsychiatric cohort; n = 71, 7 cases were initially tested positive for GAD65-Abs by ELISA), and DM1 or latent autoimmune diabetes in adults (DM1/LADA cohort ( n = 40, all were initially tested positive)). Sera were re-tested for GAD65-Abs by ELISA, CBA, and IHC. Also, we examined the possible presence of GAD67-Abs by CBA and of other neuronal autoantibodies by IHC. Samples that showed IHC patterns different from GAD65 were further tested by selected CBAs. Results ELISA retested GAD65-Abs level in patients with neuropsychiatric diseases was higher than in patients with DM1/LADA (only retested positive samples were compared; 6 vs. 38; median 47,092 U/mL vs. 581 U/mL; p = 0.02). GAD-Abs showed positive both by CBA and IHC only if antibody levels were above 10,000 U/mL, without a difference in prevalence between the studied cohorts. We found other neuronal antibodies in one patient with epilepsy (mGluR1-Abs, GAD-Abs negative), and in a patient with encephalitis, and two patients with LADA. Conclusion GAD65-Abs levels are significantly higher in patients with neuropsychiatric disease than in patients with DM1/LADA, however, positivity in CBA and IHC only correlates with high levels of GAD65-Abs, and not with the underlying diseases." @default.
• W4378232840 created "2023-05-26" @default.
• W4378232840 creator A5000558528 @default.
• W4378232840 creator A5010445763 @default.
• W4378232840 creator A5011751060 @default.
• W4378232840 creator A5025987824 @default.
• W4378232840 creator A5028212472 @default.
• W4378232840 creator A5034098961 @default.
• W4378232840 creator A5054075124 @default.
• W4378232840 creator A5064703582 @default.
• W4378232840 creator A5071255639 @default.
• W4378232840 creator A5088448770 @default.
• W4378232840 date "2023-05-25" @default.
• W4378232840 modified "2023-09-25" @default.
• W4378232840 title "Anti-GAD65 autoantibody levels measured by ELISA and alternative types of immunoassays in relation to neuropsychiatric diseases versus diabetes mellitus type 1" @default.
• W4378232840 cites W1984098406 @default.
• W4378232840 cites W1986668408 @default.
• W4378232840 cites W2007473119 @default.
• W4378232840 cites W2014191362 @default.
• W4378232840 cites W2034238826 @default.
• W4378232840 cites W2037405613 @default.
• W4378232840 cites W2058979548 @default.
• W4378232840 cites W2071047994 @default.
• W4378232840 cites W2072652145 @default.
• W4378232840 cites W2076913361 @default.
• W4378232840 cites W2078990452 @default.
• W4378232840 cites W2117009915 @default.
• W4378232840 cites W2123094571 @default.
• W4378232840 cites W2161973499 @default.
• W4378232840 cites W2328874926 @default.
• W4378232840 cites W2338123113 @default.
• W4378232840 cites W2528067317 @default.
• W4378232840 cites W2789650623 @default.
• W4378232840 cites W2804480894 @default.
• W4378232840 cites W3009841438 @default.
• W4378232840 cites W3031832795 @default.
• W4378232840 cites W3109094113 @default.
• W4378232840 cites W3130760254 @default.
• W4378232840 cites W3146363207 @default.
• W4378232840 cites W4224250750 @default.
• W4378232840 doi "https://doi.org/10.3389/fneur.2023.1111063" @default.
• W4378232840 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37305746" @default.
• W4378232840 hasPublicationYear "2023" @default.
• W4378232840 type Work @default.
• W4378232840 citedByCount "0" @default.
• W4378232840 crossrefType "journal-article" @default.
• W4378232840 hasAuthorship W4378232840A5000558528 @default.
• W4378232840 hasAuthorship W4378232840A5010445763 @default.
• W4378232840 hasAuthorship W4378232840A5011751060 @default.
• W4378232840 hasAuthorship W4378232840A5025987824 @default.
• W4378232840 hasAuthorship W4378232840A5028212472 @default.
• W4378232840 hasAuthorship W4378232840A5034098961 @default.
• W4378232840 hasAuthorship W4378232840A5054075124 @default.
• W4378232840 hasAuthorship W4378232840A5064703582 @default.
• W4378232840 hasAuthorship W4378232840A5071255639 @default.
• W4378232840 hasAuthorship W4378232840A5088448770 @default.
• W4378232840 hasBestOaLocation W43782328401 @default.
• W4378232840 hasConcept C118552586 @default.
• W4378232840 hasConcept C126322002 @default.
• W4378232840 hasConcept C134018914 @default.
• W4378232840 hasConcept C151730666 @default.
• W4378232840 hasConcept C159654299 @default.
• W4378232840 hasConcept C163764329 @default.
• W4378232840 hasConcept C203014093 @default.
• W4378232840 hasConcept C204232928 @default.
• W4378232840 hasConcept C2778186239 @default.
• W4378232840 hasConcept C2779343474 @default.
• W4378232840 hasConcept C2781232474 @default.
• W4378232840 hasConcept C555293320 @default.
• W4378232840 hasConcept C71924100 @default.
• W4378232840 hasConcept C72563966 @default.
• W4378232840 hasConcept C86803240 @default.
• W4378232840 hasConcept C90924648 @default.
• W4378232840 hasConceptScore W4378232840C118552586 @default.
• W4378232840 hasConceptScore W4378232840C126322002 @default.
• W4378232840 hasConceptScore W4378232840C134018914 @default.
• W4378232840 hasConceptScore W4378232840C151730666 @default.
• W4378232840 hasConceptScore W4378232840C159654299 @default.
• W4378232840 hasConceptScore W4378232840C163764329 @default.
• W4378232840 hasConceptScore W4378232840C203014093 @default.
• W4378232840 hasConceptScore W4378232840C204232928 @default.
• W4378232840 hasConceptScore W4378232840C2778186239 @default.
• W4378232840 hasConceptScore W4378232840C2779343474 @default.
• W4378232840 hasConceptScore W4378232840C2781232474 @default.
• W4378232840 hasConceptScore W4378232840C555293320 @default.
• W4378232840 hasConceptScore W4378232840C71924100 @default.
• W4378232840 hasConceptScore W4378232840C72563966 @default.
• W4378232840 hasConceptScore W4378232840C86803240 @default.
• W4378232840 hasConceptScore W4378232840C90924648 @default.
• W4378232840 hasLocation W43782328401 @default.
• W4378232840 hasLocation W43782328402 @default.
• W4378232840 hasLocation W43782328403 @default.
• W4378232840 hasOpenAccess W4378232840 @default.
• W4378232840 hasPrimaryLocation W43782328401 @default.
• W4378232840 hasRelatedWork W1563850031 @default.
• W4378232840 hasRelatedWork W2002377344 @default.
• W4378232840 hasRelatedWork W2005697087 @default.
• W4378232840 hasRelatedWork W2031578901 @default.
• W4378232840 hasRelatedWork W2043428857 @default.
• W4378232840 hasRelatedWork W2101875571 @default.

• next